TROLOVOL (D-penicillamine), chelating agent

TOXICOLOGY - New indication

Opinions on drugs - Posted on Sep 06 2017

Extension of indication

TROLOVOL has Marketing Authorisation in the treatment of cystinuria.
Its assessment in this indication is based on non-comparative studies of poor methodological quality. Its therapeutic benefit compared with tiopronin (ACADIONE) is unknown. The poor safety profile is likely to limit the duration of treatment in some patients.
Its dose (300 mg) is not suitable for children under 6 years of age.